Compositions and methods for reducing at least one symptom of human allergy to cats

US12012447B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-12012447-B2
Application numberUS-202217731403-A
CountryUS
Kind codeB2
Filing dateApr 28, 2022
Priority dateMay 17, 2021
Publication dateJun 18, 2024
Grant dateJun 18, 2024

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The present application provides compositions, methods, and systems for reducing allergic response to Fel D1. Such compositions, methods, and systems generally include a supplement comprising an anti-Fel D1 molecule and an animal digest.

First claim

Opening claim text (preview).

The invention is claimed as follows: 1. A supplement for reducing allergic response to Fel D1, the supplement comprising dried egg yolk powder comprising an anti-Fel D1 molecule that is anti-Fel D1-specific polyclonal immunoglobulin Y (sIgY), the supplement further comprising a dried animal digest that is thermally-treated meat-based enzymatic hydrolysate, the dried egg yolk powder is about 1 wt. % to about 30 wt. % of the supplement, the anti-Fel D1 molecule is about 0.0001 wt. % to about 1 wt. % of the supplement, and the dried animal digest is about 20 wt. % to about 80 wt. % of the supplement. 2. The supplement of claim 1 , further comprising an additive selected from the group consisting of vitamin E, vitamin C, and mixtures thereof. 3. A method of making a supplement for reducing allergic response to Fel D1, the method comprising: admixing (i) dried egg yolk powder comprising an anti-Fel D1 molecule that is anti-Fel D1-specific polyclonal immunoglobulin Y (sIgY) and (ii) a dried animal digest that is thermally-treated meat-based enzymatic hydrolysate, to form the supplement, the dried egg yolk powder is about 1 wt. % to about 30 wt. % of the supplement, the anti-Fel D1 molecule is about 0.0001 wt. % to about 1 wt. % of the supplement, and the dried animal digest is about 20 wt. % to about 80 wt. % of the supplement. 4. The method of claim 3 , further comprising admixing an additive selected from the group consisting of vitamin E, vitamin C, and mixtures thereof. 5. A system for reducing allergic response to Fel D1, comprising: a food composition, and a supplement, wherein the supplement comprises dried egg yolk powder comprising an anti-Fel D1 molecule that is anti-Fel D1-specific polyclonal immunoglobulin Y (sIgY), the supplement further comprising a dried animal digest that is thermally-treated meat-based enzymatic hydrolysate, the dried egg yolk powder is about 1 wt. % to about 30 wt. % of the supplement, the anti-Fel D1 molecule is about 0.0001 wt. % to about 1 wt. % of the supplement, and the dried animal digest is about 20 wt. % to about 80 wt. % of the supplement. 6. The system of claim 5 , wherein the food composition is a cat food. 7. A method for reducing allergic response to Fel D1, comprising: adding a supplement to a food composition, wherein the supplement comprises dried egg yolk powder comprising an anti-Fel D1 molecule that is anti-Fel D1-specific polyclonal immunoglobulin Y (sIgY), the supplement further comprising a dried animal digest that is thermally-treated meat-based enzymatic hydrolysate, the dried egg yolk powder is about 1 wt. % to about 30 wt. % of the supplement, the anti-Fel D1 molecule is about 0.0001 wt. % to about 1 wt. % of the supplement, the dried animal digest is about 20 wt. % to about 80 wt. % of the supplement; and administering the food composition to a cat. 8. The method of claim 7 , wherein administration is a regular administration.

Assignees

Inventors

Classifications

  • Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein (oligopeptides having up to five amino acids {A61K47/183}; polyamino acids A61K47/34) · CPC title

  • Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14) · CPC title

  • one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid · CPC title

  • Vitamins · CPC title

  • from waste material, e.g. feathers, bones or skin (A23K10/24 takes precedence) · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US12012447B2 cover?
The present application provides compositions, methods, and systems for reducing allergic response to Fel D1. Such compositions, methods, and systems generally include a supplement comprising an anti-Fel D1 molecule and an animal digest.
Who is the assignee on this patent?
Nestle Sa
What technology area does this patent fall under?
Primary CPC classification C07K16/18. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Jun 18 2024 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).